Thoughts, page-3

Part of the problem here is that there are a lot of stale share holders who have seen this pattern repeated again and again so that any time there is a price rise, they take the opportunity to sell off into the buying pressure.

Then there is the failure thus far of Biotron to make a commercial deal. As time progresses and the much heralded deal fails to evenuate, us shareholders are starting to wonder if it will ever happen. Surely the big pharmas have had more than enough time to look at the BIT stable of drug candidates to make an evaluation of worthiness. I have to admit that as a rusted on holder I'm starting to wonder...